Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at weekly chemotherapy for ovarian cancer (ICON 8)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared chemotherapy every week with chemotherapy every 3 weeks for ovarian cancer, fallopian tube cancer or primary peritoneal cancer. It was supported by Cancer Research UK.
More about this trial
- is better than 3 weekly chemotherapy for women with ovarian cancer
- causes more or fewer side effects than 3 weekly chemotherapy
Summary of results
- 522 women had both carboplatin and paclitaxel once every 3 weeks (group A)
- 523 women had carboplatin once every 3 weeks, and paclitaxel once a week (group B)
- 521 women had both carboplatin and paclitaxel once a week (group C)
- 24.4 months for those in group A (3 weekly chemotherapy)
- 24.9 months for those in group B (3 weekly carboplatin and weekly paclitaxel)
- 25.3 months for those in group C (weekly chemotherapy)
- 8 out of 10 (80%) of those in group A
- just over 8 out of 10 (82%) of those in group B
- just under 8 out of 10 (78%) of those in group C
How to join a clinical trial
Dr Andrew Clamp
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/10/030.